Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Inclusion criteria

• Type 2 diabetes patients with a glycated hemoglobin (HbA1c) level of 7.0 - 10.5% at screening
• Males or females aged 20-80 years
• Individuals who have been taking Metformin (≥ 500mg) with or without a DPP-4 inhibitor (such as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Alogliptin, Teneligliptin, Anagliptin, Evogliptin) for at least the past 3 months
• Body mass index ≥ 23 kg/m²
• Estimated glomerular filtration ratio (eGFR) ≥ 60 ml/min/1.73m²

Exclusion criteria

• Patients with Type 1 Diabetes, Gestational Diabetes, or secondary diabetes due to other causes
• Patients with a history of acute cardiovascular disease within the last 3 months prior to the screening visit
• Pregnant or breastfeeding patients, or patients not using contraception. Patients with chronic Hepatitis B or C (excluding healthy carriers of Hepatitis B), or liver disease (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3 times the upper limit of normal)
• Patients with heart failure or a history of heart failure
• Individuals with a history of cancer within the past 5 years (excluding those adequately treated for squamous cell carcinoma or thyroid cancer)
• Patients who have participated in another clinical study within the last 30 days
• Alcohol addiction
• Patients for whom the use of Enavogliflozin or Pioglitazone is contraindicated
• Patients taking other oral hypoglycemic agents or insulin or other investigational drugs
• Patients deemed unsuitable for the study based on the investigator's judgment